Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Antidiabetics Market size to exceed $116bn by 2023

Global Market Insights Inc.
Posted on: 30 Aug 16
Antidiabetics Market size to exceed $116bn by 2023

Antidiabetics Market size was USD 51.1 billion in 2015, with global industry growth forecast of over 10% CAGR; as per the latest research report by Global Market Insights, Inc. Rising prevalence of diabetes along with penetration of insulin analogs, and oral anti-diabetic drugs should spur global insulin antidiabetics market size. 

Aging and obesity are the key risk factors for diabetes, with affected population slated to exceed 360 million by 2023. Major diabetes consequences include blindness, amputations, and kidney failure, with higher risk of death. Increasing geriatric population, and rising obesity trend along with rising patient awareness levels are some pivotal drivers for industry growth. Global insulin antidiabetics market size was valued at USD 51.1 billion in 2015, with 10.9% CAGR gains likely during forecast period. 

A number of initiatives aimed at providing insulin and other anti-diabetic drugs to patients at a cost effective price by establishing sophisticated healthcare reimbursement network is a key global trend. Apart from this, introduction of new high-efficiency products is also expected to boost growth.

Request for a sample of this research report - https://www.gminsights.com/request-sample/detail/504  

Technology growth with products such as rapid acting, and long acting insulin analogs with higher efficacies, ultra-long acting SGLT-2 inhibitor analogs, and oral antidiabetics should further contribute to industry growth. The new insulin pen technology launch enables low-pain and convenient daily injection of insulin should also propel spur therapy sales. 

Generic drug manufacturers could tap the growth opportunity due to patent expiration of major popular products by introducing low cost and effective products. Moreover, emerging regions also offer a strong platform with unmet medical needs. Growing prevalence, large diabetic patient pool, and increasing awareness levels regarding diagnosis in the emerging Asia Pacific countries are some reasons for industry growth expectations. APAC was driven by the countries Japan, China and India antidiabetics market size, estimated at USD 28 billion by 2023.
 

Browse key industry insights spread across 71 pages with 36 market data tables & 30 figures & charts from the report, “Antidiabetics Market Size By Product (Insulin [Rapid Acting, Long Acting, Premixed, Short Acting, Intermediate Acting], Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, GLP-1 Agonist, Meglitinides, DPP-4 Inhibitors, SGLT-2, Thiazolodinediones), By Application (Type I Diabetes, Type II & Other), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023” in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/antidiabetics-market

Key insights from the report include:

·     Global antidiabetics market size was USD 51.1 billion in 2015, with over 10% industry gains up to 2023.

·     U.S. insulin antidiabetics market share was the largest in North America, with close to 24 million estimated diabetes patients, of which 23% remain undiagnosed. Various awareness campaigns and education programs are organized by associations and diabetes societies to raise awareness and provide information regarding diabetes management. 

·     However, the U.S. is maturing in terms of new product launches, due to which manufacturers are now seeking towards emerging areas in diabetes for more revenue generation. 

·    Europe antidiabetics market will show steady growth as well, particularly due to increase in obesity prevalence, with 10% to 50% of adult population diagnosed to be obese in 2015. Germany and UK insulin antidiabetic sales accounted for more than 50% of regional revenue. 

·    Asia Pacific could see 13% CAGR sales growth from 2016 to 2023, with India and China still relatively unexplored in terms of potential.

Takeda, Merck, Boehringer Ingelheim, Oramed, Pfizer, Novo Nordisk, Eli Lilly and Sanofi Aventis, are some notable industry participants.

Editor's Details

Juee Kate

Last updated on: 30/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.